Literature DB >> 30820037

Educational delay and attainment in persons with neurofibromatosis 1 in Denmark.

Karoline Doser1, Line Kenborg2, Elisabeth Wreford Andersen3, Pernille Envold Bidstrup3, Anja Kroyer2, Hanne Hove4, John Østergaard5, Sven Asger Sørensen6, Christoffer Johansen3,7, John Mulvihill8, Jeanette Falck Winther2,9, Susanne Oksbjerg Dalton3.   

Abstract

Most research on psychosocial consequences of neurofibromatosis type 1 (NF1) has focused on the relationship between disease factors and cognitive functioning. NF1 may impair domains of learning and attention, resulting in low academic performance. This study is the first nationwide population-based cohort study to investigate educational attainment and delay in completing mandatory school by persons with NF1. Educational information was collected from 550 persons at the age of 30 (born 1965-1984). They were diagnosed with NF1 in Denmark and compared to a cohort of NF1-free persons matched on gender and age (n = 4295). Multinomial logistic models were applied to estimate odds ratios (ORs) for obtaining short (≤9 years) or medium (10-12 years) education compared to long education (>12 years) by the age of 30 years. We calculated the probability of graduating 9th year of mandatory school at different ages in 932 persons with NF1 and 7962 NF1-free persons (born 1965-2000) using quantile regression. The OR of educational completion for short- and medium-term education was three fold (95% CI 2.55-3.99) and 1.29 fold (95% CI 0.99-1.69) higher, respectively, for persons with NF1 than NF1-free persons after adjusting for birth year, gender, psychiatric and somatic morbidity and mother's education. Persons with NF1 were significantly delayed in graduating mandatory school education compared to NF1-free persons. When 90% of persons have graduated, persons with NF1 were 1.2 times older than the NF1-free persons. Experiencing delays in mandatory school likely affect further educational achievements and may impair employment and entering work force.

Entities:  

Mesh:

Year:  2019        PMID: 30820037      PMCID: PMC6777448          DOI: 10.1038/s41431-019-0359-8

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  34 in total

1.  A note on robust variance estimation for cluster-correlated data.

Authors:  R L Williams
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

Review 2.  Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1.

Authors:  Rui M Costa; Alcino J Silva
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

Review 3.  The unmet needs of all adults with ADHD are not the same: a focus on Europe.

Authors:  Ylva Ginsberg; Kathleen Marie Beusterien; Kaitlan Amos; Claude Jousselin; Philip Asherson
Journal:  Expert Rev Neurother       Date:  2014-06-04       Impact factor: 4.618

4.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

5.  Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.

Authors:  J S Cohen; H P Levy; J Sloan; J Dariotis; B B Biesecker
Journal:  Clin Genet       Date:  2015-01-20       Impact factor: 4.438

6.  The Danish Psychiatric Central Research Register.

Authors:  Ole Mors; Gurli P Perto; Preben Bo Mortensen
Journal:  Scand J Public Health       Date:  2011-07       Impact factor: 3.021

7.  Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients.

Authors:  J M Friedman; P H Birch
Journal:  Am J Med Genet       Date:  1997-05-16

8.  Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

Authors:  S A Rasmussen; Q Yang; J M Friedman
Journal:  Am J Hum Genet       Date:  2001-03-28       Impact factor: 11.025

9.  An examination of lexical and sublexical reading skills in children with neurofibromatosis type 1.

Authors:  Sharon E Watt; Arthur Shores; Kathryn N North
Journal:  Child Neuropsychol       Date:  2008-09       Impact factor: 2.500

10.  Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.

Authors:  Tu Anh Duong; Emilie Sbidian; Laurence Valeyrie-Allanore; Cédric Vialette; Salah Ferkal; Smaïl Hadj-Rabia; Christophe Glorion; Stanislas Lyonnet; Michel Zerah; Isabelle Kemlin; Diana Rodriguez; Sylvie Bastuji-Garin; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2011-05-04       Impact factor: 4.123

View more
  5 in total

1.  Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online survey.

Authors:  Pamela L Wolters; Stephanie Reda; Staci Martin; Nour Al Ghriwati; Melissa Baker; Dale Berg; Gregg Erickson; Barbara Franklin; Vanessa L Merker; Beverly Oberlander; Stephanie Reeve; Claas Rohl; Tena Rosser; Mary Anne Toledo-Tamula; Ana-Maria Vranceanu
Journal:  Am J Med Genet A       Date:  2021-09-18       Impact factor: 2.578

2.  Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.

Authors:  Geohana Hamoy-Jimenez; Raymond Kim; Suganth Suppiah; Gelareh Zadeh; Vera Bril; Carolina Barnett
Journal:  Neurooncol Adv       Date:  2020-01-10

3.  Cohort profile: life with neurofibromatosis 1 - the Danish NF1 cohort.

Authors:  Karoline Doser; Hanne Hove; John R Østergaard; Pernille E Bidstrup; Susanne O Dalton; Mette Møller Handrup; Cecilie Ejerskov; Anja Krøyer; Mia Aagaard Doherty; Jens Richardt Møllegaard Jepsen; John J Mulvihill; Jeanette F Winther; Line Kenborg
Journal:  BMJ Open       Date:  2022-09-20       Impact factor: 3.006

4.  A rare disease and education: Neurofibromatosis type 1 decreases educational attainment.

Authors:  Edvard Johansson; Roope A Kallionpää; Petri Böckerman; Juha Peltonen; Sirkku Peltonen
Journal:  Clin Genet       Date:  2021-01-12       Impact factor: 4.438

Review 5.  Cutaneous Expression of Familial Cancer Syndromes.

Authors:  Anne-Johanne Andersen; Juliane Schierbeck; Anette Bygum; Nieves Puente-Pablo
Journal:  Acta Derm Venereol       Date:  2021-07-30       Impact factor: 3.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.